IRONWOOD PHARMACEUTICALS INC Logo

IRONWOOD PHARMACEUTICALS INC

Develops and commercializes therapies for GI diseases like IBS-C and chronic constipation.

IRWD | US

Overview

Corporate Details

ISIN(s):
US46333X1081
LEI:
Country:
United States of America
Address:
100 SUMMER STREET, SUITE 2300, 2110 BOSTON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Ironwood Pharmaceuticals Inc. is a gastrointestinal (GI) healthcare company focused on advancing the treatment of GI diseases. As a commercial-stage biotechnology firm, its core activities involve the research, development, and commercialization of innovative therapies for patients with digestive disorders. The company maintains a singular focus on the GI field, leveraging specialized expertise to address unmet medical needs and redefine the standard of care. Its primary commercial product is LINZESS® (linaclotide), a leading prescription treatment for adults with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all IRONWOOD PHARMACEUTICALS INC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for IRONWOOD PHARMACEUTICALS INC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for IRONWOOD PHARMACEUTICALS INC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
MedinCell S.A. Logo
Develops long-acting injectable therapies using proprietary technology to impact global health.
France MEDCL
A CDMO for cell therapy and regenerative medicine development & manufacturing.
Japan 2370
Medios AG Logo
Compounding patient-specific therapies and supplying specialty pharma for complex conditions.
Germany ILM1
Develops cord blood stem cell therapies for osteoarthritis & infant lung disease, plus banking.
South Korea 078160
MediWound Ltd. Logo
Develops enzymatic therapies for non-surgical tissue repair in burns and chronic wounds.
United States of America MDWD
Medizen Humancare Inc Co., Ltd Logo
Offers DTC genetic testing and genomic analysis for personalized disease risk prediction.
South Korea 236340
Medy-Tox Inc. Logo
Develops and markets botulinum toxins and dermal fillers for global aesthetic & therapeutic use.
South Korea 086900
MeiraGTx Holdings plc Logo
Develops genetic medicines for eye, salivary gland, and CNS disorders using gene regulation tech.
United States of America MGTX
Meito  Sangyo  Co., Ltd. Logo
Produces food products and specialty chemicals for industrial and pharmaceutical applications.
Japan 2207
Merck & Co., Inc. Logo
A global biopharma developing innovative medicines, vaccines, and animal health products.
United States of America MRK

Talk to a Data Expert

Have a question? We'll get back to you promptly.